Densidade mineral ossea em usuarias de contraceptivos injetaveis combinados

AUTOR(ES)
DATA DE PUBLICAÇÃO

2006

RESUMO

BACKGROUND: The objective of this study was to compare bone mineral density (BMD) between users of two kinds of once-a-month combined injectable contraceptives (CIC) and controls. SUBJECTS AND METHODS: This crosssectional study included 97 women of 20 to 45 years of age, using CIC containing either 25 mg of medroxyprogesterone acetate and 5 mg of estradiol cypionate (MPA/E2Cyp, Cyclofemina) (for 12 to 82 months) or 50 mg of norethindrone enanthate and 5mg of estradiol valerate (NET-EN/E2Val, Mesigyna) (for 12 to 60 months) matched by age (± 1 year) and body mass index (BMI, kg/m2) (± 1) with users of the TCu 380A intrauterine device as controls. BMD was evaluated at the midshaft of the ulna and at the distal section of the radius of the nondominant forearm using double X-ray absorptiometry. RESULTS: The BMD at the midshaft of the ulna was 0.457 ± 0.007 and 0.465 ± 0.007 in the MPA/oE2Cyp group and controls, respectively, and 0.463 ± 0.008 and 0.458 ± 0.009 in the NET-EN/oE2Val group and controls, respectively. At the distal radius, the BMD was 0.399 ± 0.011 and 0.401 ± 0.010 in users of MPA/oE2Cyp and controls, respectively and 0.400 ± 0.009 and 0.388 ± 0.010 in users of NET-EN/oE2Val and controls, respectively. There were no differences in BMD between users of either CIC and non-users at either section of the forearm studied. There were also no differences in BMD between users of the two CIC at either section of the forearm. CONCLUSIONS: Women aged 20 to 45 years old, currently using one of these two kinds of CIC, presented similar BMD to controls paired by age and BMI (kg/m2) and similar between both CIC

ASSUNTO(S)

injectable contraceptives bone mineral density densidade ossea anticoncepção anticoncepcionais injetaveis contraception

ACESSO AO ARTIGO

Documentos Relacionados